# Aroxxen® Inhalation for Cardioprotection After Elective PCI With Stent Implantation

Study · id `cardio:ct-nct07397351` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07397351](<https://clinicaltrials.gov/study/NCT07397351>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07397351

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 180 participants.

## Technical summary

Registry record NCT07397351. Randomized; no masking; primary purpose supportive care. Start 2026-03-05 (actual); primary completion 2026-10-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose supportive care
- Phase: Phase 2
- Enrolled: 180 participants (planned count; ClinicalTrials.gov record NCT07397351, source copy `cardio:ctgov-nct07397351-2026-05-06`, retrieved 2026-10-26)
- Started: 2026-03-05 (actual) (ClinicalTrials.gov record NCT07397351, source copy `cardio:ctgov-nct07397351-2026-05-06`, retrieved 2026-10-26)
- Primary completion: 2026-10-01 (anticipated) (ClinicalTrials.gov record NCT07397351, source copy `cardio:ctgov-nct07397351-2026-05-06`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT07397351, source copy `cardio:ctgov-nct07397351-2026-05-06`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT07397351, source copy `cardio:ctgov-nct07397351-2026-05-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07397351-2026-05-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Aroxxen® Inhalation for Cardioprotection After Elective PCI With Stent Implantation
- Condition: Coronary Artery Disease
- Intervention (Drug): Aroxxen
- Lead sponsor: Research Institute of Geroprotective Technologies
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)

## Provenance

Content hash: 10f8cbba998fade52fb034a7d3620d8c6b88fc9cff3662982e3fc26f493a4cfd
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
